Mental Health Startup Funding 2025-2026

What are all the funding deals in the mental health market from August 2025 to September 2026?

The table below lists every qualifying disclosed equity round raised between August 2025 and September 2026 by companies whose primary activity fits the mental health market. We define the mental health market as services and products that diagnose, treat, or clinically manage recognized mental and substance use disorders, including licensed providers, facilities, medications, and clinically validated digital treatment tools.

Each row shows the company, what it does, its category, the announcement month, funding stage, deal size, region, and the main investors identified in the supplied dataset. For a wider view of the companies, funding patterns, and opportunities shaping the sector, see our Mental Health market report.

How active has fundraising been in the mental health market?

As of September 2026, fundraising in the mental health market has produced 26 qualifying disclosed equity rounds and $816.77M of capital over the 12-month study period. The dataset contains 26 unique companies, so every qualifying company appears only once.

Deal flow averages 1.86 rounds per calendar month in the supplied monthly calculations, with a median of 2.00. This is a relatively steady transaction count, but the dollar flow behind those transactions is much less stable.

Average monthly capital is $58.34M, compared with a median of $40.75M. February 2026 alone contributed $314.7M, while February and March together generated $481.7M, or 58.98% of the full-period total.

This means the mental health market should not be judged from one monthly funding headline. Deal activity is recurring, but capital arrives in bursts around a small number of scaled companies.

For a deeper look at current company activity and funding momentum, see our mental health market funding report.

How concentrated has fundraising been in the mental health market?

As of September 2026, fundraising in the mental health market is highly concentrated at the top over the 12-month study period. The largest deal represents 25.71% of all disclosed capital, the top 3 represent 53.87%, and the top 5 represent 64.89%.

The top 10 rounds absorb $672M, or 82.28% of the $816.77M total. That leaves only $144.77M spread across the other 16 qualifying financings.

Talkiatry alone raised $210M, followed by Grow Therapy at $150M and Salma Health at $80M. Together those three deals contribute $440M, meaning more than half of all market capital comes from only 11.54% of transactions.

This concentration makes aggregate mental health funding totals useful but incomplete. A rising headline number can reflect one or two scaled companies without implying that financing conditions improved equally across the rest of the market.

How much of the mental health funding signal is driven by outliers?

As of September 2026, outliers drive a substantial part of the mental health funding signal over the 12-month study period. The three rounds strictly above $50M contribute $440M, leaving $376.77M once those megarounds are removed.

The difference between the $31.41M average round and the $17M median shows the same distortion. The average is roughly 85% higher than the median, so it is not a good representation of the typical financing.

Two rounds alone exceed $100M: Talkiatry at $210M and Grow Therapy at $150M. They represent only 7.69% of deals but 44.08% of all disclosed capital.

The practical reading rule is simple: use the median and the sub-$50M capital pool alongside the headline total. They give a better picture of the financing environment facing most mental health companies.

We examine this concentration and the companies driving it in more detail in our deeper analysis of the mental health market.

Is the mental health market broad with many targets, or narrow with few fundable companies?

As of September 2026, the mental health market is broader by company count than its capital concentration initially suggests. The 12-month study period contains 26 qualifying deals across 26 different companies rather than repeated rounds from a handful of issuers.

There is also real breadth across company maturity. Seed accounts for 7 deals, Series A for 8, Series B for 5, Series C for 2, Series D+ for 2, and another 2 rounds have unknown stages.

However, breadth in company count does not translate into equal financing capacity. Fifteen of 26 rounds are below $20M, while the three largest deals alone account for more than half of all capital.

The mental health market therefore has a reasonably broad set of fundable companies but a much narrower set of companies capable of attracting very large institutional checks. That distinction matters when judging whether the market is genuinely deep.

Is the mental health market mostly an early-stage formation market or a late-stage scaling market?

As of September 2026, the mental health market combines active early-stage formation with much heavier late-stage capital deployment over the 12-month study period. Seed and Series A produce 15 of 26 deals but attract only $233.90M, or 28.64% of total capital.

Series B, Series C and Series D+ together attract $552M, or 67.58% of disclosed capital. Among known-stage rounds only, the split becomes 29.76% early stage versus 70.24% late stage.

Series D+ is the clearest example. Only Talkiatry and Grow Therapy sit in that stage, yet their combined $360M represents 44.08% of all disclosed mental health funding.

Seed tells the reverse story. Seven seed financings raise only $33.4M, with a median of $1.6M, suggesting investors continue to fund experimentation but reserve much larger checks for businesses with demonstrated clinical and reimbursement scale.

For more context on how capital shifts as companies mature, see our mental health market report covering funding stages.

Which categories attract the most investor attention in the mental health market?

As of September 2026, Therapy Care Providers attract the broadest investor attention in the mental health market over the 12-month study period. They account for 10 of 26 deals and $309.80M, representing 38.46% of transactions and 37.93% of disclosed capital.

Mental Health Clinics rank second by activity with 6 deals and $205M. Clinical Mental Health Apps also produce 6 deals, but those financings total only $54.97M.

Addiction Treatment Services contribute 3 deals and $37M, while Psychiatry Care Platforms contribute only one deal. That single Talkiatry round is large enough to give the category $210M and 25.71% of all market capital.

The deal-count data therefore suggest that therapy, clinics and clinical software are the categories where investors are testing the largest number of companies. Psychiatry looks much larger on dollars than it does on breadth.

Which categories attract disproportionately large checks in the mental health market?

As of September 2026, Psychiatry Care Platforms attract the most disproportionately large checks in the mental health market over the 12-month study period. The category has a capital-share-to-deal-share ratio of 6.68x because Talkiatry alone raised $210M.

Mental Health Clinics are the only other major category above parity, at 1.09x. Their six deals raise $205M, with a $34.17M average and $25.50M median round size.

Therapy Care Providers sit almost exactly at parity with a 0.99x ratio. Their 38.46% share of deals is closely matched by a 37.93% share of capital, making therapy one of the least distorted categories in the dataset.

Clinical Mental Health Apps sit at only 0.29x, while Addiction Treatment Services sit at 0.39x. Investors are financing multiple companies in both categories, but with materially smaller checks than the care-delivery businesses receiving scale capital.

For a category-by-category view of where capital is concentrating, explore our full mental health market deck.

Which geographies matter most for fundraising in the mental health market?

As of September 2026, North America overwhelmingly dominates fundraising in the mental health market over the 12-month study period. The region contributes 25 of 26 qualifying deals and $815.77M, equal to 99.88% of all disclosed capital.

The average North American financing is $32.63M and the median is $17M. Those figures are therefore effectively the same benchmarks as the overall mental health dataset.

Europe contributes only one qualifying transaction: Nul's $1M seed financing. That gives Europe 3.85% of deal count but only 0.12% of capital.

Asia-Pacific, Latin America, the Middle East and Africa contribute no qualifying deals under the strict pure-play clinical definition. The observed market is therefore overwhelmingly a North American venture-financing story.

Is the mental health opportunity set geographically broad or concentrated in one hub?

As of September 2026, the mental health opportunity set is geographically concentrated in one dominant hub over the 12-month study period. North America holds 96.15% of qualifying deals and 99.88% of disclosed capital.

This is stronger than a normal regional lead. Removing North America leaves only one $1M European financing in the entire qualifying dataset.

The geographic imbalance also limits how broadly the funding results can be generalized. The dataset is strong evidence about the U.S.-led clinical mental health venture ecosystem, but much weaker evidence about global capital availability.

The absence of qualifying financings in four major regions is itself informative. Under a strict clinical and pure-play definition, internationally diversified venture activity remains difficult to observe in public funding announcements.

Is the mental health market a market of small experiments or scaled financings?

As of September 2026, the mental health market contains both small experiments and scaled financings over the 12-month study period, but the typical round remains firmly below megaround size. The overall median is $17M even though the average reaches $31.41M.

Six deals are below $5M, nine fall from $5M to below $20M, seven fall from $20M to below $50M, and four are $50M or larger. More than half of all transactions therefore remain below $20M.

Only three financings are strictly above $50M: Talkiatry at $210M, Grow Therapy at $150M and Salma Health at $80M. Radial's exactly $50M financing belongs in the $50M+ size bucket but not in the strictly-above-$50M megaround count.

This distribution makes the mental health market a two-speed financing environment. Most companies raise conventional venture rounds, while a small number of scaled care platforms command checks large enough to reshape aggregate statistics.

For more detail on round sizes, major companies and current financing patterns, see our mental health market report on funding trends.

Who are the investors that appear the most in mental health fundraising?

As of September 2026, no single investor dominates mental health fundraising across the 12-month study period. General Catalyst, AlleyCorp and .406 Ventures each appear in three qualifying rounds, while Town Hall Ventures appears in two.

General Catalyst appears in Birches Health, Radial and InStride Health. These investments span addiction treatment, interventional psychiatry and pediatric specialty care rather than one narrow product category.

AlleyCorp appears in Birches Health, Big Health and Vanna Health, while .406 Ventures appears in FamilyWell Health, Big Health and InStride Health. Town Hall Ventures appears in Marble Health and Jimini Health.

The repeat-investor pattern is much weaker than the concentration of dollars at the company level. The mental health market's largest rounds are supported by a broader syndicate base rather than one or two funds repeatedly financing nearly every major winner.

Investor participation also should not be confused with investor check size. Public announcements usually disclose the total round amount rather than the exact amount contributed by each participating fund.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.